201 ELLIOTT AVENUE WEST, SEATTLE, WA
Other Events
Shareholders Elect Class II Directors and Approve Compensation Plan
Reports First Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET
Annual Report to Security Holders
Financial Results, Press Release
Earnings Release
FDA Approves YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Automatic Shelf Registration Statement
Post-Effective Amendment to Registration Statement
Free Writing Prospectus
Prospectus filed pursuant to Rule 305(b)(2)